Tesla
TSLA
MicroStrategy
MSTR
Salesforce
CRM
MARA Holdings
MARA
Apple
AAPL
US Stock MarketDetailed Quotes
CARM Carisma Therapeutics
- 0.449
- -0.036-7.46%
Trading Dec 13 10:55 ET
18.74MMarket Cap-0.29P/E (TTM)
0.480High0.441Low231.96KVolume0.475Open0.485Pre Close107.53KTurnover1.03%Turnover RatioLossP/E (Static)41.75MShares3.16052wk High-1.69P/B10.10MFloat Cap0.44152wk Low--Dividend TTM22.51MShs Float51.357Historical High--Div YieldTTM7.96%Amplitude0.441Historical Low0.463Avg Price1Lot Size
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Carisma Therapeutics Stock Forum
Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline
Monday, 9th December at 8:30 am
Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies
Development of CT-0525 to be discontinued; workforce reduced by 34%
PHILADELPHIA, Dec. 9, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused ...
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024
Carisma Therapeutics (NASDAQ: CARM) presented promising preclinical data on engineered macrophages for treating liver fibrosis at AASLD The Liver Meeting® 2024. The research shows that macrophages can be genetically engineered to target specific pathways in liver disease using factors like TIM4, relaxin, an...
Will you ever get your ass up? 😭 😭 😭
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
Carisma Therapeutics (NASDAQ: CARM) announced positive pre-clinical data for its anti-GPC3 in vivo CAR-M therapy for hepatocellular carcinoma (HCC), developed with Moderna. The therapy demonstrated ability to create CAR-M directly in vivo, reprogramming myeloid cells to target GPC3-expressing cancer cells. Pre-clinical results showed specificity fo...
Moderna news / collaboration.
Yet no movement. 🧐🤔
Carisma and Moderna Expand Collaboration to Develop Two in Vivo Car-M Therapies for Autoimmune Diseases
No comment yet